Thus, therapeutically targeting systemic properdin and therefore ameliorating the alternative complement system with mAb 1340 could be effective and feasible in locally complement-mediated diseases like arthritis or abdominal aortic aneurysm [25]. This evidence concerns the gene CFP and arthritic joint disease.